Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: Business Wire
FDA Grants Fast Track Designation for Ivonescimab in 2L+ EGFRm NSCLCHARMONi Completed Enrollment for Summit’s First Sponsored Study Evaluating IvonescimabTopline data from the HARMONi Trial Is Expected in Mid-2025 MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that we have completed enrollment in our HARMONi clinical trial, a multi-regional Phase III study sponsored by Summit evaluating ivonescimab plus platinum-doublet chemotherapy vs. placebo plus platinum-doublet chemotherapy with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with a 3rd generation EGFR tyrosine kinase inhibitor (TKI). HARMONi completed enrolling patients from sites in North America, Europe, and China. This is a clinical setting with a patient population where PD-1 monoclonal antibodies have previously been unsuccessful in Phase I
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Summit Therapeutics (SMMT) Hurt Bronte Capital. Here's Why [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.MarketBeat
- Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now? [Yahoo! Finance]Yahoo! Finance
- BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential [Yahoo! Finance]Yahoo! Finance
SMMT
Earnings
- 10/30/24 - Beat
SMMT
Sec Filings
- 10/30/24 - Form 10-Q
- 10/30/24 - Form 8-K
- 10/15/24 - Form 4
- SMMT's page on the SEC website